Pain is one of the most common symptoms in advanced melanoma, but its severity, timing, and character vary enormously depending on where the cancer has spread and how far it has progressed. Roughly four in ten melanoma patients experience pain at some point in their disease, and that proportion climbs sharply in later stages. The honest answer is that dying from melanoma can involve significant pain, but it does not have to be uncontrolled, and the experience differs so much from person to person that no single description captures it.
How Common Is Pain in Melanoma, and When Does It Appear?
Early-stage melanoma is usually painless. A mole that changes shape or color might itch or bleed, but the kind of deep, persistent pain people fear is rare until the cancer has advanced. A study of more than 300 melanoma patients found an overall pain prevalence of about 38%, but the numbers were vastly different across stages. Compared to stage I patients, those at stage II were roughly 17 times more likely to report pain. At stage III, the odds jumped to about 90 times higher, and at stage IV they reached over 230 times higher.1Rev. dor. Prevalence of pain among melanoma patients Those numbers make pain sound inevitable in late-stage disease, but they reflect odds ratios relative to a very-low-pain baseline at stage I. The practical message is that pain is uncommon when melanoma is caught early and becomes increasingly likely as it spreads.
Among patients with many types of advanced cancer, not just melanoma, pain ranks among the most prevalent symptoms alongside fatigue, weakness, lack of energy, and loss of appetite.2American Journal of Hospice and Palliative Medicine®. The Relationship Between Symptom Prevalence and Severity and Cancer Primary Site in 796 Patients With Advanced Cancer Melanoma is not uniquely painful compared to other cancers, but it is not spared, either. What does set melanoma apart is the wide range of places it can spread, each of which produces a different kind of pain.
Where the Pain Comes From
Melanoma is notorious for metastasizing to almost any organ. The site of the metastasis largely determines what kind of pain a person feels and how severe it becomes.
Bone and Muscle
When melanoma reaches bone or skeletal muscle, it can cause anything from a dull ache to sharp, debilitating pain. A review of patients with solitary bone and muscle metastases found that about 39% had mild local symptoms, while 15% reported severe pain. Another 15% were completely asymptomatic, their metastases discovered only on imaging.3PubMed Central. Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome Bone metastases are particularly problematic because the tumor can weaken the bone itself, raising the risk of fractures that cause sudden, acute pain on top of the chronic baseline.
Brain
Melanoma has a high affinity for the brain. Brain metastases commonly cause headaches, neurological deficits such as weakness or vision changes, and seizures. These tumors also tend to bleed spontaneously because they invade blood vessels early.4PubMed Central. Malignant metastatic melanoma in brain with unknown primary origin: a case report Headache from brain metastases often feels different from a typical headache: it may be worst in the morning, worsen with coughing or straining, and resist ordinary painkillers. When bleeding occurs inside the brain, the onset can be sudden and severe. For many patients and families, these neurological symptoms are more frightening than pain elsewhere in the body, because they can alter consciousness and personality.
Gastrointestinal Tract
Melanoma is one of the cancers most likely to metastasize to the gut. Patients with gastrointestinal metastases often present with vague abdominal pain, constipation, or bloating rather than a single sharp pain.5PubMed Central. Melanoma and the Gastrointestinal Tract: Maintaining a High Index of Suspicion The nonspecific nature of these symptoms is a double problem: the discomfort is real but can be mistaken for something benign, delaying recognition that the cancer has spread. Obstruction or perforation of the bowel can escalate abdominal pain dramatically and may require emergency intervention.
Skin and Soft Tissue
When melanoma grows outward through the skin, it can form what clinicians call a fungating wound: an open, ulcerated mass that breaks through the tissue surface. These wounds are painful because the tumor destroys tissue layers, cuts off local blood supply, and triggers ongoing inflammation and necrosis. They also bleed easily and may produce a persistent odor from bacterial colonization of the dead tissue.6Journal of Hospice & Palliative Nursing. Management of Fungating Tumors and Pressure Ulcers in a Patient With Stage IV Cutaneous Malignant Melanoma For patients and caregivers, fungating wounds represent one of the most distressing aspects of advanced melanoma because they are visible, painful, and difficult to manage at home.
How Symptoms Change in the Final Weeks
The last months of life with advanced melanoma bring a shifting mix of symptoms, not just pain. A study tracking patients with advanced skin cancer found that pain and loss of appetite were the most common symptoms throughout the final three months. As death approached, other symptoms piled on. Difficulty breathing, drowsiness, and anemia became increasingly frequent in the last two weeks and final days, even though they had been uncommon three months earlier.7The Journal of Dermatology. Symptom prevalence in patients with advanced skin cancer Performance status, a rough measure of how well someone can carry out daily activities, declined steadily throughout that period.
In addition to pain and appetite loss, bleeding from tumor sites, wound discharge, and offensive odor are symptoms that appear characteristically in unresectable skin cancer.8PubMed. Symptoms of and Palliative Treatment for Unresectable Skin Cancer This cluster of symptoms means that the experience of dying from melanoma is rarely about pain alone. Fatigue can become so profound that the person is bedbound. Breathing may become labored. Drowsiness deepens. For many patients, the gradual loss of consciousness in the final days means they are less aware of pain at the very end, though this is not something families can count on, and it does not mean pain management should be deferred.
Treatment Side Effects That Blur the Picture
Melanoma treatment has been transformed by immunotherapy drugs called checkpoint inhibitors, which have extended median survival for metastatic melanoma from about six months to nearly six years.9ScienceDirect. The Hidden Dilemmas of Immunotherapy in Patients With Melanoma at End-of-life That is a remarkable shift, but it introduces a complication when it comes to pain. Checkpoint inhibitors work by unleashing the immune system, and sometimes the immune system attacks the body’s own tissues, causing joint pain, muscle inflammation, nerve damage, gut inflammation, or other painful reactions. These side effects can mimic the pain that the cancer itself would cause.
Distinguishing between pain from the tumor and pain from treatment has become a significant clinical challenge.10Supportive Care in Cancer. Pain spectrum in immune checkpoint inhibitor-related adverse events: evolution, characteristics and management challenges based on bibliometrics This matters because the treatment approaches are different. Tumor pain might call for stronger painkillers or radiation to shrink a metastasis, while immune-related pain might require steroids or a temporary pause in immunotherapy. If you or a family member are dealing with new or worsening pain during melanoma treatment, flagging it early gives the medical team the best chance of figuring out the cause and adjusting the plan.
What Palliative Care Can Do About Pain
Palliative care is often misunderstood as giving up. In reality, it is a parallel track focused on comfort and quality of life that can run alongside curative or life-extending treatment. For melanoma patients, palliative care involvement tends to happen too late. A retrospective study from a comprehensive cancer center emphasized that earlier and more systematic palliative care involvement could reduce emergency department visits and improve quality of life near the end of life.11PubMed Central. End‑of‑life care in advanced melanoma: a retrospective cohort study from an Italian comprehensive cancer center
The toolkit for managing cancer pain is broad. Standard analgesic medications, ranging from anti-inflammatories to opioids, form the backbone. Beyond pills and patches, newer techniques like ultrasound-guided nerve blocks can deliver anesthetic directly to the nerves carrying pain signals from a tumor. Studies of these blocks in cancer patients have shown improved pain relief and reduced need for opioids, though the duration of benefit varies and the evidence base is still growing.12PubMed. Ultrasound-Guided Peripheral Nerve Blocks: A Practical Review for Acute Cancer-Related Pain Radiation therapy can also be used palliatively to shrink painful bone or soft tissue metastases, often providing relief within days to weeks.
For the small number of patients whose suffering remains severe despite all available treatments, palliative sedation exists as a last resort. This involves using medication to reduce a person’s awareness in order to relieve otherwise uncontrollable pain or distress at the very end of life.13PubMed Central. Ethical decision making with end-of-life care: palliative sedation and withholding or withdrawing life-sustaining treatments It is uncommon, but knowing it exists can be reassuring for patients and families who fear that uncontrolled pain is somehow inevitable. It is not. Modern palliative medicine has tools to address even the most severe cases, and no one should be told there is nothing more that can be done for their pain.
The Emotional Weight of Advanced Melanoma
Pain in the final stages of melanoma is not purely physical. Anxiety and depression are common, and they can amplify the perception of physical pain. Among patients with stage III melanoma, roughly 28% met thresholds for anxiety and 19% for depression. Among stage IV patients, those numbers were about 20% and 16%, respectively.14PubMed Central. Exploring the Psychological Experiences of Patients With Melanoma: A Narrative Review The slightly lower anxiety rate at stage IV compared to stage III may reflect a grim kind of adaptation; by the time someone is living with widespread disease, the initial shock has sometimes receded into a different emotional register.
Factors like fatigue, reduced ability to do everyday tasks, and the unpredictability of the disease all contribute to lower overall well-being. The uncertainty of prognosis weighs heavily. Immunotherapy can produce dramatic responses in some patients and fail completely in others, making it genuinely impossible to predict an individual’s trajectory. For some patients, this uncertainty is itself a form of suffering that sits alongside physical pain and deserves direct attention from the care team. Psychological support, whether through counseling, psychiatric medication, or structured support groups, is a legitimate part of managing the pain of advanced melanoma in its broadest sense.
What Patients Feel vs. What Others See
One of the quieter problems in end-of-life care is the gap between what a dying person actually experiences and what family members or even doctors think they experience. A study of terminally ill cancer patients found that both family caregivers and palliative care physicians tended to underestimate patients’ quality of life compared to the patients’ own reports. The differences were both statistically and clinically meaningful, and they were largest early in the observation period.15PubMed. Assessing agreement between terminally ill cancer patients’ reports of their quality of life and family caregiver and palliative care physician proxy ratings
This cuts in a direction that might surprise people. It means that family members watching a loved one die from melanoma often assume the experience is worse than the patient reports it to be. That does not mean the patient is fine or that their pain is not real. But it does suggest that the fear of witnessing suffering may exceed the suffering itself, at least in some cases. For patients who can still communicate, being asked directly about their pain and comfort level, rather than having it assumed, makes a real difference to care quality. And for families, understanding this gap can provide some measure of relief during an extraordinarily difficult time.
Fungating Wounds and the Burden on Caregivers
Among the aspects of advanced melanoma that receive too little public attention, fungating wounds rank high. These open, tumor-driven wounds occur when melanoma grows through the skin surface, and they present challenges that go well beyond pain. The bleeding risk is constant because the tissue is highly vascular. Wound dressings need frequent changing. The odor from necrotic tissue can be difficult to control even with specialized products, and it affects the patient’s willingness to be around other people.
For family caregivers providing home-based care, managing these wounds is physically and emotionally demanding. The combination of visible tumor, bleeding, odor, and the need for careful wound care creates a burden that standard discussions of “cancer pain” do not capture. Pain management in this context includes not just analgesics but also wound-care strategies, topical treatments, and sometimes palliative radiation to reduce the size and bleeding of the mass. Specialized palliative wound-care nursing, when available, can significantly ease the burden on both patient and caregiver.
The Role of Lymph Node Surgery in Pain After Melanoma
An underappreciated source of pain among melanoma patients is not the cancer itself but the surgery used to stage or treat it. In the study of pain prevalence among melanoma patients, more than half of those reporting pain attributed it to lymph node dissection performed after identification of a positive sentinel node or clinically suspicious lymph nodes. A smaller proportion linked their pain to the sentinel lymph node biopsy procedure itself.1Rev. dor. Prevalence of pain among melanoma patients Only about 20% said their pain was at the site of the original melanoma.
This is worth knowing because it reframes the question of pain in melanoma. A significant portion of the pain burden falls not on people dying from the disease but on survivors and people still in treatment who are living with chronic post-surgical discomfort. Lymph node dissection, especially in the groin or armpit, can cause lasting nerve damage, swelling from disrupted lymph drainage, and reduced range of motion. These complications are manageable, but they require recognition. If your pain after melanoma surgery persists for months, it is not something to just push through. It is a known consequence that deserves targeted treatment, including physical therapy and nerve-pain medications.
How Immunotherapy Has Changed the End-of-Life Landscape
Before checkpoint inhibitors arrived around 2011, metastatic melanoma had a median survival of roughly six months. The conversation about dying from melanoma was different then: the decline was fast, and the window for managing symptoms was narrow. With modern immunotherapy pushing median survival toward six years for metastatic disease, the trajectory has stretched out.9ScienceDirect. The Hidden Dilemmas of Immunotherapy in Patients With Melanoma at End-of-life The five-year survival rate for metastatic melanoma remains around 30%, meaning the majority of patients still eventually die of the disease, but the path to that endpoint is longer and more complex.
This longer timeline creates new dilemmas. Patients may continue immunotherapy very close to the end of life, hoping for a late response, even when the treatment is causing significant side effects. Deciding when to shift focus entirely to comfort can be agonizing for patients, families, and oncologists alike. The boundary between “fighting the cancer” and “managing the dying” has become blurrier than it once was. For patients navigating this, an early relationship with a palliative care team, ideally starting well before the last weeks of life, gives you the best shot at having pain controlled and your goals for care honored, whether those goals include continuing treatment or prioritizing comfort.